RedHill Biopharma traded at $1.15 this Monday February 2nd, decreasing $0.07 or 5.74 percent since the previous trading session. Looking back, over the last four weeks, RedHill Biopharma lost 17.86 percent. Over the last 12 months, its price fell by 80.44 percent. Looking ahead, we forecast RedHill Biopharma to be priced at 1.18 by the end of this quarter and at 1.09 in one year, according to Trading Economics global macro models projections and analysts expectations.
Redhill Biopharma Ltd is an Israel-basedis a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The Company promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.